evidence table
Ginseng Cognitive Performance Randomized Trial Evidence Table
Structured evidence table for Ginseng Cognitive Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Ginseng Cognitive Performance Randomized Trial | Ginsenosides are the prime pharmacologically active compounds responsible for the medicinal properties of ginseng, which are also found in many otherspecies, includingand. | 3 | Cortés Hernán (2026) | Ginsenoside Rg1 as a Multifunctional Therapeutic Agent: Pharmacological Properties, Molecular Mechanisms and Clinical Perspectives in Complementary Medicine |
| Ginseng Cognitive Performance Randomized Trial | Some studies have reported reduced plasma concentrations of warfarin and enhanced aspirin bioavailability after ginseng intake, indicating possible pharmacokinetic and pharmacodynamic interactions. | 3 | Cortés Hernán (2026) | Ginsenoside Rg1 as a Multifunctional Therapeutic Agent: Pharmacological Properties, Molecular Mechanisms and Clinical Perspectives in Complementary Medicine |
| Ginseng Cognitive Performance Randomized Trial | Alzheimer's disease (AD) is a result of a neurodegenerative process, which is associated with beta‐amyloid deposition and neurofibrillary tangles formation (Wang et al. ). | 3 | Cortés Hernán (2026) | Ginsenoside Rg1 as a Multifunctional Therapeutic Agent: Pharmacological Properties, Molecular Mechanisms and Clinical Perspectives in Complementary Medicine |
| Ginseng Cognitive Performance Randomized Trial | AD Akt AMP AMPK APP/Aβ AUC BBB [Ca] CaN CaSR Cl C CNS CYP CYP‐7A DMT1 DMT2 EMT FoxO1 FSH G6Pase GLUT4 GRg1 GSK‐3β Haspin HD HO‐1 HSC IC IL‐1β LDL LH LPS MAPKs MPTP mRNA MRT NF‐κB nNOS NO OGD PC12 PD PDGF PEPCK PINK PPARγ PPD SAMP8 SMAD Smad7 SNpc SREBP‐1C T TGF‐β1 TLR T TNF‐α V VEGF Panax ginseng P. | 3 | Cortés Hernán (2026) | Ginsenoside Rg1 as a Multifunctional Therapeutic Agent: Pharmacological Properties, Molecular Mechanisms and Clinical Perspectives in Complementary Medicine |
| Ginseng Cognitive Performance Randomized Trial | Cognitive disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, depression, and vascular dementia, are associated with dysregulation of neurotransmitter systems, including acetylcholine, dopamine, serotonin, glutamate, and γ-aminobutyric acid (GABA). | 4 | Rahman M (2026) | Herbal Neurotherapeutics for Cognitive Disorders: Integrative Mechanisms Linking Neurotransmitter Systems, Neurodegeneration, and the Gut-Brain Axis. |
| Ginseng Cognitive Performance Randomized Trial | Current pharmacological therapies may provide symptomatic relief; however, their clinical benefits are often limited and associated with adverse effects. | 4 | Rahman M (2026) | Herbal Neurotherapeutics for Cognitive Disorders: Integrative Mechanisms Linking Neurotransmitter Systems, Neurodegeneration, and the Gut-Brain Axis. |
| Ginseng Cognitive Performance Randomized Trial | Preclinical evidence and emerging clinical studies suggest that herbal bioactive compounds may exert neuroprotective effects through antioxidants, anti-inflammatory, and neurotransmitter-modulating mechanisms. | 4 | Rahman M (2026) | Herbal Neurotherapeutics for Cognitive Disorders: Integrative Mechanisms Linking Neurotransmitter Systems, Neurodegeneration, and the Gut-Brain Axis. |
| Ginseng Cognitive Performance Randomized Trial | These disorders are increasingly recognized as multifactorial conditions involving oxidative stress, neuroinflammation, mitochondrial dysfunction, synaptic impairment, blood-brain barrier disruption, metabolic imbalance, and gut-brain axis dysregulation. | 4 | Rahman M (2026) | Herbal Neurotherapeutics for Cognitive Disorders: Integrative Mechanisms Linking Neurotransmitter Systems, Neurodegeneration, and the Gut-Brain Axis. |
Source documents
- Ginsenoside Rg1 as a Multifunctional Therapeutic Agent: Pharmacological Properties, Molecular Mechanisms and Clinical Perspectives in Complementary Medicine
- Herbal Neurotherapeutics for Cognitive Disorders: Integrative Mechanisms Linking Neurotransmitter Systems, Neurodegeneration, and the Gut-Brain Axis.